Related Experiment Video

Updated: Oct 25, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.7K

Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled

Sherif Abbass1, Ehab Kamal2, Mohsen Salama1

  • 1National Liver Institute, Shebeen El-Kom, Menoufia, Egypt.

Journal of Medical Virology
|August 11, 2021
PubMed

Insights

Sofosbuvir plus daclatasvir (SOF-DCV) significantly improved symptoms and oxygen saturation in COVID-19 patients compared to standard care. This repurposed antiviral combination offers a safe and effective treatment option for moderate to severe coronavirus disease-2019.

Area of Science:

  • Virology
  • Infectious Diseases
  • Clinical Pharmacology

Background:

  • Limited approved treatments exist for COVID-19.
  • Repurposing existing antiviral drugs is a rapid strategy for effective therapy.
  • Evaluating novel combinations for moderate to severe COVID-19 is crucial.

Purpose of the Study:

  • To assess the efficacy and safety of sofosbuvir (SOF) plus daclatasvir (DCV) or ravidasvir (RDV) combined with standard of care (SOC) for COVID-19.
  • To compare outcomes between SOF-DCV/RDV plus SOC versus SOC alone.
  • To evaluate clinical endpoints including symptom resolution, oxygen saturation, and ICU admission.

Main Methods:

  • A multicentre, parallel, randomized controlled, open-label trial.
  • 120 patients with moderate to severe COVID-19 were randomized.
  • 10-day treatment with SOF-DCV or SOF-RDV plus SOC, compared to SOC alone, with 7-day follow-up.

Main Results:

  • SOF-DCV plus SOC significantly reduced symptom burden and prevented deterioration (ICU admission, mechanical ventilation) compared to SOC alone.
  • Oxygen saturation significantly improved in the SOF-DCV group from Day 4.
  • SOF-RDV plus SOC did not demonstrate significant improvements in primary endpoints.

Conclusions:

  • Sofosbuvir plus daclatasvir (SOF-DCV) is effective and safe as an add-on therapy for moderate to severe COVID-19.
  • This combination shows promise in improving clinical outcomes and preventing severe disease progression.
  • Ravidasvir combination did not yield significant benefits in this study.
Keywords:
COVID-19daclatasvirrepurposing antiviral drugssofosbuvir

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-208:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.0K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.1K

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
27
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
39
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
36
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
233
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.9K